Status of tumor markers in ovarian cancer screening.

@article{Bast2003StatusOT,
  title={Status of tumor markers in ovarian cancer screening.},
  author={Robert C. Bast},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2003},
  volume={21 10 Suppl},
  pages={
          200s-205s
        }
}
One of the most promising approaches to management of ovarian cancer is early detection. Stage I ovarian cancer can be cured with currently available therapy in more than 90% of patients. However, fewer than 25% of ovarian cancers are currently detected in stage I. Detection of a greater fraction of cancers at an early stage might improve clinical outcome. Given a prevalence of one patient with ovarian cancer among 2,500 asymptomatic postmenopausal women in the general population, a successful… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 112 CITATIONS, ESTIMATED 70% COVERAGE

HE4 as an Early Detection Biomarker of Epithelial Ovarian Cancer: Investigations in Prediagnostic Specimens From the Janus Serumbank.

  • International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • 2015
VIEW 4 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Mesothelin as a biomarker for targeted therapy

  • Biomarker Research
  • 2019
VIEW 1 EXCERPT
CITES BACKGROUND

FILTER CITATIONS BY YEAR

2003
2019

CITATION STATISTICS

  • 3 Highly Influenced Citations